Di- Cal Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 26-07-2024
- Paid Up Capital ₹ 2.50 M
as on 26-07-2024
- Company Age 16 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.38 Cr
as on 26-07-2024
- Revenue -97.23%
(FY 2023)
- Profit 72.80%
(FY 2023)
- Ebitda -1619.21%
(FY 2023)
- Net Worth -22.03%
(FY 2023)
- Total Assets -60.01%
(FY 2023)
About Di- Cal Pharma
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company has closed loans amounting to ₹1.38 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sangeeta Barot, Sharadbhai Patel, Ashokbhai Barot, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24110GJ2008PTC055370
- Company No.
055370
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Chhatral, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Di- Cal Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashokbhai Barot  | Director | 06-Nov-2008 | Current |
| Sangeeta Barot | Director | 06-Nov-2008 | Current |
| Sharadbhai Patel | Director | 06-Nov-2008 | Current |
Mukurdhvaj Barot  | Director | 06-Nov-2008 | Current |
| Asmitaben Patel | Director | 15-Feb-2020 | Current |
Financial Performance of Di- Cal Pharma.
Di- Cal Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 97.23% decrease. The company also saw a substantial improvement in profitability, with a 72.8% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Di- Cal Pharma?
In 2023, Di- Cal Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Spa Vet-Min Private LimitedActive 17 years 11 monthsSangeeta Barot, Sharadbhai Patel and 1 more are mutual person
- Tierra Fertilizer Private LimitedActive 4 years 4 months
Sangeeta Barot and Ashokbhai Barot are mutual person
- Aviraj Charitable FoundationActive 2 years 5 months
Sangeeta Barot and Ashokbhai Barot are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 27 Jun 2009 | ₹1.38 Cr | Satisfied |
How Many Employees Work at Di- Cal Pharma?
Unlock and access historical data on people associated with Di- Cal Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Di- Cal Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Di- Cal Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
